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Abstract
Adjuvant hormonal therapy for postmenopausal women with early
stage breast cancer has become far more complex over the past
several years. This commentary reviews the current status of the five
major trials evaluating the use of the aromatase inhibitors in the
adjuvant setting. The data currently available suggest that the
aromatase inhibitors are efficacious either as upfront therapy or
after a course of tamoxifen. Ongoing trials will compare these
approaches and guide the use of these agents in the years to come.
Adjuvant hormonal therapy for postmenopausal women with
hormone receptor positive breast cancer has become far
more complex over the past several years. Before this period,
the standard of care for postmenopausal women with early
stage, estrogen receptor positive breast cancer was
treatment for 5 years with tamoxifen, which reduced the
annual risk for disease recurrence by almost 50% [1].
Tamoxifen is associated with the rare, but potentially fatal,
side effects of endometrial cancer and venous thrombosis,
but long-term follow up from multiple studies revealed a
highly favorable risk–benefit ratio.
A growing body of data has demonstrated that the aromatase
inhibitors may further decrease the risk for breast cancer
recurrence. Five major randomized trials have contributed to
our understanding of the role of the aromatase inhibitors in
the adjuvant setting. Two of these trials, the Anastrozole or
Tamoxifen Alone or in Combination (ATAC) trial and the
International Breast Cancer Study Group’s BIG 1-98 trial
compared an aromatase inhibitor (letrozole) versus tamoxifen
as initial hormonal therapy in the adjuvant setting [2-4]. Three
other trials have employed crossover strategies; the
Intergroup Exemestane Study (IES) and the Austrian Breast &
Colorectal Cancer Study Group (ABCSG) Trial 8/German
ARNO 95 trial (anastrozole) compared a crossover to an
aromatase inhibitor versus continued tamoxifen in women
who had completed 2–3 years of tamoxifen [5,6]. The MA-17
trial compared the use of letrozole with placebo after 5 years
of tamoxifen [7].
The primary end-point of these trials was disease-free or
event-free survival, although the precise definition of this end-
point varied somewhat across trials. Regardless of the exact
definition, each trial demonstrated a decrease in breast
cancer events in women who had received an aromatase
inhibitor. At a median of 68 months of follow up, the ATAC
trial demonstrated a hazard ratio (HR) of 0.83 (95%
confidence interval [CI] 0.73–0.94) for women with hormone
receptor positive breast cancer treated with anastrozole [2].
The absolute difference in events between anastrozole and
tamoxifen was 3.3% at 6 years. No survival difference has yet
been demonstrated. The BIG 1-98 trial also demonstrated a
significantly lower rate of breast cancer events in the
aromatase inhibitor arm [4]. With a median follow up of
25.8 months, the HR for a breast cancer recurrence, second
breast or nonbreast malignancy, or death from any cause was
0.81 (95% CI 0.70–0.93) in the letrozole arm as compared
with the tamoxifen arm. Not surprisingly, given the short follow
up of the trial, there was no difference in overall survival. Of
note, there was a nonsignificant increase in nonbreast cancer
related deaths in the letrozole arm, with an excess of cardiac
and cerebrovascular deaths in this group (P = 0.08).
The crossover trials also demonstrated significantly lower
rates of breast cancer events in patients treated with an
aromatase inhibitor. The patient populations in these trials
were somewhat different from those in ATAC and BIG 1-98,
because patients were free of disease after 2–3 years of
tamoxifen. In IES the HR for a recurrence of breast cancer, a
contralateral cancer, or death from any cause at 30.6 months
was 0.68 (95% CI 0.56–0.82) in the exemestane arm, which
corresponded to a 4.7% absolute difference in event rates
between the two groups [6]. The exemestane group also had
a significantly lower risk for distant relapse (HR 0.66, 95% CI
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0.52–0.83) and for contralateral breast primary. In the
ABCSG/ARNO trial, the HR for a locoregional recurrence, a
distant recurrence, or a contralateral breast cancer at 3 years
was 0.60 (95% CI 0.44–0.81) in the crossover group
compared with the group treated with 5 years of tamoxifen
[5]. Again, there was a significantly lower risk for distant
relapse in the anastrozole group (HR 0.61, 95% CI
0.42–0.87) but no significant difference in overall survival at
the time of this initial analysis.
The MA-17 trial looked the role of extended adjuvant
endocrine therapy [7]. Women who completed 5 years of
tamoxifen were randomly assigned to 5 years of letrozole or to
placebo. The trial was stopped at the time of the first interim
analysis, with a median follow up of 2.4 years. The letrozole
arm demonstrated a significantly better disease-free survival,
with a HR of 0.57 (95% CI 0.43–0.75). The actuarial 4 year
disease-free survival was 93% for the letrozole arm and 87%
for the placebo arm (P < 0.001). An update presented at the
2004 American Society of Clinical Oncology meeting [8]
reported a marginally significant (P = 0.04) survival advantage
for lymph node positive patients treated with letrozole. This
trial, along with the crossover trials described above,
demonstrated that sequential therapy with tamoxifen followed
by an aromatase inhibitor is clearly more effective in preventing
breast cancer events than tamoxifen alone.
In addition to examining the efficacy of the drugs, the adjuvant
trials have also examined the tolerability and toxicity of the
aromatase inhibitors [9,10]. In general, the drugs were well
tolerated, with low rates of discontinuation due to adverse
events. Many side effects, such as hot flashes, mood
changes and weight gain, were similar in patients treated with
aromatase inhibitors and tamoxifen. Patients treated with the
aromatase inhibitors developed significantly more osteo-
porosis and fractures than did those treated with tamoxifen,
but they did not appear to have the increased risk for clotting
and endometrial pathology that has been seen with tamoxifen.
The BIG 1-98 trial did demonstrate an excess of cardiac
disease and deaths in patients treated with letrozole [4], and
the ATAC study demonstrated an excess of approximately 20
nonbreast cancer related deaths in the anastrozole arm [3].
Although these differences did not reach statistical
significance, further evaluation of the impact of aromatase
inhibitors on women’s overall health is needed. Unfortunately,
the early stopping of several of the aromatase inhibitor trials
based on the efficacy of the drugs may make it difficult to fully
evaluate their toxicity.
There is consensus that the optimal adjuvant hormonal
therapy for postmenopausal women with hormone receptor
positive breast cancer should include an aromatase inhibitor
in most settings [11]. However, the ‘best’ use of an
aromatase inhibitor remains unclear. It is not known at this
time whether women are best served by starting an
aromatase inhibitor as initial therapy or by taking tamoxifen for
a number of years followed by an aromatase inhibitor. Further
data from the crossover arms of the BIG 1-98 trial may
provide an answer to this question, but it will be several years
before these data are mature. In the interim, three groups
have designed models to evaluate the relative benefits of
different treatment strategies [12,13]. A Markov model from
our institution suggests that a crossover from tamoxifen to an
aromatase inhibitor after 2–3 years may be the preferred
strategy for the typical patient, in order to minimize the
chance of recurrence over a 10- to 15-year time span [12].
Although such models can be helpful in analyzing complex
data from a number of sources, they do not substitute for
randomized clinical trials and are highly dependent on a
range of assumptions. However, the models do emphasize
the importance of ongoing crossover trials such as BIG 1-98.
In the absence of an early survival benefit, it will be critical to
allow these trials to proceed and the planned crossover data
to mature so that it will be possible to determine whether initial
aromatase inhibitor therapy or a crossover approach offers the
best protection against subsequent breast cancer events.
A single approach may not be optimal for all patients. Based
on characteristics of the tumor and patient, it is likely that
different women will benefit from differing hormonal therapy
strategies. Subset analyses of the ATAC and ABCGS/ARNO
trials have suggested that the use of an aromatase inhibitor
may be especially beneficial in women with estrogen
receptor-positive and progesterone receptor-negative tumors
[5,14], and preoperative studies have demonstrated that
aromatase inhibitors may also be more effective in women
whose tumors are estrogen-receptor positive and
overexpress the HER2 protein [15]. Gene microarray profiling
has suggested that there may be signatures associated with
resistance to tamoxifen [16], and it is possible that the
aromatase inhibitors may be more effective in this setting as
well. Hormone receptor positive breast cancer is comprised
of at least three distinct tumor types as defined by clinical
characteristics, single gene markers, and microarray analyses
[17]: luminal A (typically estrogen receptor-positive,
progesterone receptor-positive, and low grade); luminal B
(typically higher grade); and HER2-positive with coexpression
of steroid hormone receptors. Each of these tumor types may
require a somewhat different approach. Finally, as we gain a
better understanding of the toxicity profile of the aromatase
inhibitors, we may be able to predict which women are at
greatest risk for side effects and who might therefore be
considered better candidates for a shorter course of an
aromatase inhibitor after tamoxifen or, in some situations,
tamoxifen alone.
The aromatase inhibitors represent a major advance in
adjuvant hormonal therapy for postmenopausal women with
breast cancer. The current standard of care for a
postmenopausal woman with early stage breast cancer
would clearly include the use of an aromatase inhibitor, either
upfront or after some period of tamoxifen use. Given the257
available data, it is difficult to conclude that one approach is
superior to another. It is also important to remember that upfront
use of an aromatase inhibitor probably precludes the use of
other aromatase inhibitors after 5 years of therapy, an approach
that demonstrated significant benefit in the MA-17 trial.
There are currently many unanswered questions regarding the
optimal hormonal therapy regimen for postmenopausal women
with early stage breast cancer. Recently completed and
ongoing studies will address many of these issues, and it is
important to withhold final judgment regarding the use of the
aromatase inhibitors and tamoxifen until these data are
available. The aromatase inhibitors clearly represent an
advance in hormonal therapy for postmenopausal women. Over
the next few years, several trials will help to guide their optimal
use to guarantee that women in the years ahead will gain an
ever-increasing benefit from adjuvant hormonal therapy.
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